QNCX

Quince Therapeutics, Inc.

NASDAQ: QNCX · HEALTHCARE · BIOTECHNOLOGY

$1.26

-8.18% today

Updated 2026-06-05

Market cap

$17.80M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-9.67

Dividend yield

—

52W range

$1 – $46

Volume

46.7M

Market cap

$17.80M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-9.67

Dividend yield

—

52W range

$1 – $46

Volume

46.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-8.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$5.00

+296.83%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.03x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -8.93 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-7.63M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-51.66M	$-31.39M	$-56.83M	$-83.98M	$35.91M
EPS	—	—	—	—	$-9.67
Free cash flow	$-44.17M	$-18.45M	$-32.16M	$-41.78M	$-7.63M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
QNCX	$17.80M	23	4.3	3.0	5.0	5.5	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Quince Therapeutics, Inc. trades at $1.26. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -8.93, it sits in the distress.

Frequently asked questions

What is Quince Therapeutics, Inc.'s stock price?

Quince Therapeutics, Inc. (QNCX) trades at $1.26.

Is Quince Therapeutics, Inc. overvalued?

Quince Therapeutics, Inc. carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Quince Therapeutics, Inc. (QNCX)?

The 12-month analyst consensus target is $5.00, about 296.8% above the current $1.26. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Quince Therapeutics, Inc.'s Altman Z-Score is -8.93, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-210.80%

Beta1.46

50D MA$1.20

200D MA$13.57

Shares out0.02B

Float0.02B

Short ratio—

Avg volume46.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

QNCX vs LLY →QNCX vs JNJ →QNCX vs ABBV →Stock screener →